title: [Pharmacological studies on the clathrate compound of mobenzoxamine with beta-cyclodextrin. (I). Effects on the digestive system].
abstract: Effects of the clathrate compound of mobenzoxamine (MBX) with beta-cyclodextrin (MBX-CD), a new gastro-intestinal function modulator, on the digestive system were studied in comparison with those of metoclopramide, domperidone and trimebutine. MBX-CD showed inhibitory effects that were approximately 1/4 times as potent as metoclopramide on both apomorphine- and copper sulfate-induced emesis and about 1/40 times as potent as domperidone on apomorphine-induced emesis in dogs. In rats, MBX-CD enhanced gastric emptying as potently as metoclopramide, and only MBX-CD showed a clear amelioration of the delayed gastric emptying induced by BaCl2. Similarly, only MBX-CD showed an ameliorative effect on small intestinal transport accelerated by BaCl2 in mice. Though both MBX and trimebutine inhibited spontaneous contractions of the isolated guinea pig stomach and rabbit intestine, it seemed that the properties of these effects were different from those of papaverine. On isolated guinea pig ileum, MBX inhibited contractions induced by various agonists equally to or more potently than trimebutine or papaverine. The results suggest that MBX-CD or MBX acts extensively on the gastro-intestinal system for the reason that it has not only the respective properties of the gastro-intestinal function modulators used as the standards, but also its own characteristic effects.
authors.affiliation: Department of Pharmacology, Kyoto Pharmaceutical University, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Yokochi
authors.forename: S
authors.initials: S
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Ohata
mesh_terms: D000818:Animals; D000932:Antiemetics; D001646:Bile / Q000378:metabolism; D002090:Butyrophenones / Q000494:pharmacology*; D003505:Cyclodextrins / Q000494:pharmacology*; D003912:Dextrins / Q000494:pharmacology*; D004285:Dogs; D004294:Domperidone / Q000494:pharmacology; D004338:Drug Combinations; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005753:Gastric Mucosa / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D051379:Mice; D010879:Piperazines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D013213:Starch / Q000494:pharmacology*; D014287:Trimebutine / Q000494:pharmacology; D047392:beta-Cyclodextrins
chemical_list: D000932:Antiemetics; D002090:Butyrophenones; D003505:Cyclodextrins; D003912:Dextrins; D004338:Drug Combinations; D010879:Piperazines; D047392:beta-Cyclodextrins; D004294:Domperidone; D013213:Starch; C031215:betadex; D008787:Metoclopramide; C059408:mobenzoxamine; D014287:Trimebutine